Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Isoniazid

FDA-approved product (tablet, oral), marketed as Dow-Isoniazid, Hyzyd, Inh and 5 more.

Registered studies
50+
Lab records
268
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Isoniazid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Pulmonary tuberculosis
  • Silicosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hydrazides
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AC01; WHO ATC J04AC51; FDA class Antimycobacterial

Repurposing investigation

Isoniazid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA8.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli7.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 241 of 268 lab records
Open Isoniazid in ChEMBL Registered studies below
Show the latest 150 of 268 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Isoniazid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

    NCT06568484 · start 2026-05-08

    Registered record
    Registry ID
    NCT06568484
    Conditions
    Tuberculosis, Latent
    Interventions
    Bedaquiline; Isoniazid, rifapentine; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-05-08
    Completion
    2027-09
    Enrolment
    2,530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Latent
    InterventionBedaquiline; Isoniazid, rifapentine; Levofloxacin
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

    NCT07118696 · start 2026-02-01

    Registered record
    Registry ID
    NCT07118696
    Conditions
    Pulmonary TB
    Interventions
    Extra 600mg of Rifampicin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-02-01
    Completion
    2030-01-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary TB
    InterventionExtra 600mg of Rifampicin; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

    NCT07086820 · start 2025-10-27

    Registered record
    Registry ID
    NCT07086820
    Conditions
    Tuberculosis Infection; Household Contacts; Children; Adolescent; Tuberculosis Infection, Latent; Tuberculosis
    Interventions
    Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks; Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-27
    Completion
    2028-11
    Enrolment
    647

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Infection; Household Contacts; Children; Adolescent +2 more
    InterventionTuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks; Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks
    PhaseNot applicable
    Registry statusRecruiting

  • A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

    NCT06748937 · start 2025-03-03

    Registered record
    Registry ID
    NCT06748937
    Conditions
    Tuberculosis
    Interventions
    Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-03
    Completion
    2026-03-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionAlpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    PhasePhase 2
    Registry statusRecruiting

  • Intensified Short Course Regimen for TBM in Adults

    NCT05917340 · start 2024-03

    Registered record
    Registry ID
    NCT05917340
    Conditions
    Tuberculous Meningitis
    Interventions
    High dose rifampicin (25mg/kg); Moxifloxacin 400mg; Aspirin 150 mg; Isoniazid; Pyrazinamide; Steroid; Rifampicin; HRZE; HRE
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2024-03
    Completion
    2027-09
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculous Meningitis
    InterventionHigh dose rifampicin (25mg/kg); Moxifloxacin 400mg; Aspirin 150 mg; Isoniazid +5 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • ATORvastatin in Pulmonary TUBerculosis

    NCT06199921 · start 2024-01-03

    Registered record
    Registry ID
    NCT06199921
    Conditions
    Pulmonary Tuberculosis; Tuberculosis; Koch's Disease
    Interventions
    Atorvastatin 20mg; Atorvastatin 40mg; Atorvastatin 60mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-03
    Completion
    2026-09-30
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis; Tuberculosis; Koch's Disease
    InterventionAtorvastatin 20mg; Atorvastatin 40mg; Atorvastatin 60mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

    NCT05971602 · start 2023-07-26

    Registered record
    Registry ID
    NCT05971602
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS); Isoniazid and Rifampicin (HR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-07-26
    Completion
    2025-02-06
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionDelamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) +1 more
    PhasePhase 2
    Registry statusTerminated

  • Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

    NCT05473520 · start 2023-05-24

    Registered record
    Registry ID
    NCT05473520
    Conditions
    Tuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)
    Interventions
    Doxycycline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-05-24
    Completion
    2030-01-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)
    InterventionDoxycycline; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)

    NCT05534750 · start 2023-04-20

    Registered record
    Registry ID
    NCT05534750
    Conditions
    Tuberculosis; Multidrug Resistant Tuberculosis
    Interventions
    Tedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-20
    Completion
    2026-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Tuberculosis
    InterventionTedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    PhasePhase 2
    Registry statusRecruiting

  • Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

    NCT05401071 · start 2023-01-13

    Registered record
    Registry ID
    NCT05401071
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Short Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2023-01-13
    Completion
    2027-11-01
    Enrolment
    2,442

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionShort Regimen with Rifapentine 10mg/kg; Standardized Regimen; Short Regimen with Rifapentine 15mg/kg; Short Regimen with Rifapentine 20mg/kg
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

    NCT05592223 · start 2022-12-06

    Registered record
    Registry ID
    NCT05592223
    Conditions
    Tuberculosis
    Interventions
    BCG Vaccine USP; Isoniazid; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-12-06
    Completion
    2023-12-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionBCG Vaccine USP; Isoniazid; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Azacytidine During Anti-tuberculosis Therapy

    NCT03941496 · start 2022-10

    Registered record
    Registry ID
    NCT03941496
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Azacitidine Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2022-10
    Completion
    2023-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionAzacitidine Injection
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Safety of Administering Isoniazid to SLE Patients to Prevent TB

    NCT06618573 · start 2022-08-15

    Registered record
    Registry ID
    NCT06618573
    Conditions
    Tuberculosis; Systemic Lupus Erythematosus
    Interventions
    Isoniazid/Pyridoxine; Saccharum Lactis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2022-08-15
    Completion
    2025-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Systemic Lupus Erythematosus
    InterventionIsoniazid/Pyridoxine; Saccharum Lactis
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Triage Test for All Oral DR-TB Regimen (TRiAD Study)

    NCT05175794 · start 2022-05-26

    Registered record
    Registry ID
    NCT05175794
    Conditions
    Drug Resistant Tuberculosis; MDR-TB; XDR-TB; Tuberculosis
    Interventions
    Xpert® MTB/XDR
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-05-26
    Completion
    2025-06-01
    Enrolment
    786

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Resistant Tuberculosis; MDR-TB; XDR-TB; Tuberculosis
    InterventionXpert® MTB/XDR
    PhaseNot recorded
    Registry statusCompleted

  • Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

    NCT04951986 · start 2021-08-11

    Registered record
    Registry ID
    NCT04951986
    Conditions
    Disseminated Tuberculosis; HIV
    Interventions
    Rifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-11
    Completion
    2026-03
    Enrolment
    732

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisseminated Tuberculosis; HIV
    InterventionRifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone +1 more
    PhasePhase 3
    Registry statusActive not recruiting